Clinical trial
Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201…
NCT00313261 · Bukwang Pharmaceutical, Industry · Terminated
Key facts
| NCT number | NCT00313261 |
|---|---|
| Title | Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group |
| Official title | An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of L-FMAU (Clevudine) in Chronic Hepatitis B Patients of L-FMAU-201 Placebo Group |
| Lead sponsor | Bukwang Pharmaceutical, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | Clevudine |
| Start date | Jun 1, 2003 |
| Completion | Feb 1, 2005 |
| First posted | Apr 12, 2006 |
| Last update posted | Oct 17, 2012 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: